NOVIOGENDIX HOLDING
NovioGendix, a privately-held molecular diagnostics company focused on the development of a non-invasive liquid biopsy test for prostate cancer. NovioGendix, based in Nijmegen (The Netherlands), is a molecular diagnostic company providing an expert-based, integrated approach in developing advanced and clinically useful molecular diagnostic assays for uro-oncological practice. NovioGendix has a range of diagnostic tests for prostate, bladder, kidney and other urologic cancers in various stag... es of development. Commencing activities in 2008 as a Radboud University Medical Center (Radboudumc) spin-off company, NovioGendix has a standing cooperation with various Radboudumc departments. The main shareholders of NovioGendix include BioGeneration Ventures, and Participatiemaatschappij Oost Nederland.
NOVIOGENDIX HOLDING
Industry:
Health Care
Founded:
2006-01-01
Address:
Nijmegen, Gelderland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.noviogendix.nl
Total Employee:
1+
Status:
Closed
Contact:
866.259.5644
Email Addresses:
[email protected]
Technology used in webpage:
Domain Not Resolving
Official Site Inspections
http://www.noviogendix.nl
- Host name: 23.227.38.67
- IP address: 23.227.38.67
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "Noviogendix Holding"
Noviogendix Holding - Crunchbase Company Profile & Funding
NovioGendix, a privately-held molecular diagnostics company focused on the development of a non-invasive liquid biopsy test for prostate cancer. NovioGendix, based in Nijmegen (The …See details»
Noviogendix Holding - CoBee Company Profile & Funding Rounds
NovioGendix, a privately-held molecular diagnostics company focused on the development of a non-invasive liquid biopsy test for prostate cancer. NovioGendix, based in Nijmegen (The …See details»
NovioGendix Company Profile 2024: Valuation, Investors
NovioGendix General Information Description. Provider of molecular diagnostics and services to physicians, clinics, and hospitals. The company offers service to conduct test for prostate …See details»
NovioGendix - Oost NL
Een belangrijk aspect voor Oost NL om in te stemmen met de deal met het beursgenoteerde MDxHealth was dat het bedrijf op de huidige locatie kan blijven zitten om nauw te kunnen …See details»
NovioGendix - Company Profile & Staff Directory - ContactOut
NovioGendix® is acronym of Noviomagum (Latin for Nijmegen) Gene based molecular diagnostics(dix). Founded in 2006, NovioGendix offers Molecular Diagnostics Services …See details»
Dealmaker | NovioGendix
NovioGendix, based in Nijmegen (The Netherlands), is a molecular diagnostic company providing an expert-based, integrated approach in developing advanced and clinically useful molecular …See details»
Dutch company acquired by MDxHealth - BioVox
Sep 21, 2015 The Dutch biotech company NovioGendix is acquired by the Belgian company MDxHealth. MDxHealth will pay $ 8.8 million (€ 7.8 million) for the Nijmegen-based company. …See details»
NovioGendix - VentureRadar
NovioGendix offers molecular diagnostics services through its accreditated laboratory, and performs research in the field of the discovery of new diagnostic markers for cancer. …See details»
NovioGendix - Products, Competitors, Financials, Employees ...
NovioGendix is a privately-held molecular diagnostics company focused on the development of a non-invasive liquid biopsy test for prostate cancer. Use the CB Insights Platform to explore …See details»
NovioGendix Holding BV: Drug pipelines, Patents, Clinical trials
Jun 17, 2023 Explore NovioGendix Holding BV with its drug pipeline, therapeutic area, technology platform, .See details»
Novio gendix - jack schalken 25032010 | PPT - SlideShare
Apr 23, 2012 1) Noviogendix is a spin-off company from Radboud University Nijmegen Medical Center that focuses on molecular diagnostics, specifically in oncology and infectious diseases. …See details»
NovioGendix Holding B.V. - life-sciences-europe.com
Upcoming Events. BMSS-BSPR Super Meeting 2024 Warwick (BMSS 2024) Morgan Stanley Global Healthcare Conference 2024 New York; Goldman Sachs European Medtech and …See details»
NovioGendix - BioGeneration Ventures
NovioGendix is developing a new biomarker panel for the detection and management of prostate cancer and other cancers. In 2010 MDxHealth acquired NovioGendix. Year 2007 Field …See details»
MDx Health Buys NovioGendix for Up to $8.8M - genengnews.com
Sep 15, 2015 MDx Health plans to acquire NovioGendix for up to $8.8 million, the companies said today, in a deal that expands the buyer’s uro-oncology offerings with a noninvasive urine …See details»
NovioGendix CEO, Founder, Key Executive Team, Board of …
NovioGendix Management Team2 Team Members. NovioGendix has 2 executives. NovioGendix's current Chief Executive Officer is Bastiaan deLeeuw. Name. Work History. …See details»
MDx Health Buys NovioGendix for Up to $8.8M - Inside Precision …
Sep 15, 2015 NovioGendix was founded in 2007 by Jack A. Schalken, Ph.D., and Willem Melchers, Ph.D., and began operations the following year as a Radboud University Medical …See details»
MDxHealth's $8.8M acquisition of NovioGendix is a liquid biopsy …
Sep 16, 2015 MDxHealth announced that it is buying the Netherlands' NovioGendix for up to $8.8 million to get its hands on liquid biopsy technology for diagnosing prostate cancer, as …See details»
Novigenix Company Profile 2024: Valuation, Funding & Investors
Novigenix General Information Description. Developer of a precision medicine platform designed for the detection of disease, therapy optimization, and disease recurrence monitoring to …See details»
NovioGendix Coverage - MedCity News
Molecular diagnostics company MDxHealth and partner NovioGendix have been awarded a $1.1 million grant that will be applied toward research and development of a new bladder cancer …See details»
Novigenix - the leading Immuno-Transcriptomics company
The leading Immuno-Transcriptomics company: Generating insights from tumor-host interaction in order to detect cancer as early as possible and tailor the right treatment for the right patient.See details»